# US 2013/0157962 A1 · Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine a or other cyclophilin inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157962 A1
- Document ID: US20130157962A1
- Status: Published application
- Kind: A1
- Application number: 13/746,843
- Filed: 2013-01-22
- Published: 2013-06-20
- Earliest claimed: 2004-11-04
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Charles V. Clevenger
- Web page: https://patentgrep.com/patent/US20130157962A1

## CPC

- A61K 38/13: Cyclosporins
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin.

## Claims

### Claim 1

A method for inhibiting growth of prolactin-responsive cancer cells comprising administering to the cells an agent which directly inhibits an enzymatic activity of a cyclophilin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the cyclophilin is cyclophilin A.

### Claim 3 (depends on 1)

The method of claim 1 wherein the agent is a cyclosporine.

### Claim 4 (depends on 1)

The method of claim 1 wherein the agent is cyclosporine A.

### Claim 5 (depends on 4)

The method of claim 4 wherein the cyclosporine A is administered at a significantly lessened dosage as compared to that used in immunosuppressive therapies.

### Claim 6 (depends on 1)

The method of claim 1 wherein the prolactin-responsive cancer cells are breast cancer cells.

### Claim 7 (depends on 1)

The method of claim 1 wherein the prolactin-responsive cancer cells are prostate cancer cells.

### Claim 8

A method for treating a prolactin-responsive malignancy in a subject comprising administering to the subject an agent which directly inhibits an enzymatic activity of cyclophilins.

### Claim 9 (depends on 8)

The method of claim 8 wherein the cyclophilin is cyclophilin A.

### Claim 10 (depends on 8)

The method of claim 8 wherein the agent is a cyclosporine.

### Claim 11 (depends on 8)

The method of claim 8 wherein the agent is cyclosporine A.

### Claim 12 (depends on 11)

The method of claim 11 wherein the cyclosporine A is administered at a significantly lessened dosage as compared to that used in immunosuppressive therapies.

### Claim 13 (depends on 8)

The method of claim 8 wherein the prolactin-responsive malignancy is breast cancer.

### Claim 14 (depends on 8)

The method of claim 8 wherein the prolactin-responsive malignancy is prostate cancer.
